Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis

Documenti analoghi

• Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
  di: Pegah Golabi, et al.
  Pubblicazione: (2024)
• Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
  di: Raj Vuppalanchi, et al.
  Pubblicazione: (2024)
• Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
  di: Sung Won Chung, et al.
  Pubblicazione: (2024)
• Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
  di: Wenjun Meng, et al.
  Pubblicazione: (2024)
• Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
  di: Pojsakorn Danpanichkul, et al.
  Pubblicazione: (2024)